Sanofi (NASDAQ:SNY) Shares Sold by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. lowered its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 63.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,002,632 shares of the company's stock after selling 1,777,833 shares during the period. Alyeska Investment Group L.P.'s holdings in Sanofi were worth $48,357,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Abel Hall LLC increased its stake in shares of Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company's stock worth $530,000 after acquiring an additional 194 shares in the last quarter. Providence Capital Advisors LLC increased its holdings in shares of Sanofi by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock valued at $2,653,000 after acquiring an additional 201 shares in the last quarter. Keudell Morrison Wealth Management grew its position in Sanofi by 1.7% during the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock valued at $624,000 after purchasing an additional 217 shares during the last quarter. Bailard Inc. lifted its stake in shares of Sanofi by 1.4% in the fourth quarter. Bailard Inc. now owns 16,359 shares of the company's stock worth $789,000 after buying an additional 220 shares in the last quarter. Finally, Bessemer Group Inc. grew its holdings in shares of Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after buying an additional 242 shares during the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Trading Down 2.6 %

SNY stock traded down $1.44 during trading on Tuesday, hitting $53.15. The company had a trading volume of 3,507,793 shares, compared to its average volume of 2,357,653. The firm has a market capitalization of $134.27 billion, a P/E ratio of 21.35, a PEG ratio of 1.01 and a beta of 0.55. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The company has a 50 day simple moving average of $54.51 and a 200-day simple moving average of $52.04.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sanofi's revenue was down 11.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.78 EPS. As a group, research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a dividend of $2.0369 per share. This represents a yield of 3.1%. The ex-dividend date is Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is 57.14%.

Analyst Ratings Changes

A number of analysts have commented on SNY shares. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a report on Monday, April 28th. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. BNP Paribas began coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.